Cost-utility analysis of a national project to reduce hypertension in Israel

<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs:...

Full description

Bibliographic Details
Main Authors: Dicker Dror, Viskoper Reuven, Ginsberg Gary, Yosefy Chaim, Gavish Dov
Format: Article
Language:English
Published: BMC 2007-11-01
Series:Cost Effectiveness and Resource Allocation
Online Access:http://www.resource-allocation.com/content/5/1/16
id doaj-fb23f1be3d104a30bfbcaf39704ed271
record_format Article
spelling doaj-fb23f1be3d104a30bfbcaf39704ed2712020-11-25T02:28:57ZengBMCCost Effectiveness and Resource Allocation1478-75472007-11-01511610.1186/1478-7547-5-16Cost-utility analysis of a national project to reduce hypertension in IsraelDicker DrorViskoper ReuvenGinsberg GaryYosefy ChaimGavish Dov<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p> http://www.resource-allocation.com/content/5/1/16
collection DOAJ
language English
format Article
sources DOAJ
author Dicker Dror
Viskoper Reuven
Ginsberg Gary
Yosefy Chaim
Gavish Dov
spellingShingle Dicker Dror
Viskoper Reuven
Ginsberg Gary
Yosefy Chaim
Gavish Dov
Cost-utility analysis of a national project to reduce hypertension in Israel
Cost Effectiveness and Resource Allocation
author_facet Dicker Dror
Viskoper Reuven
Ginsberg Gary
Yosefy Chaim
Gavish Dov
author_sort Dicker Dror
title Cost-utility analysis of a national project to reduce hypertension in Israel
title_short Cost-utility analysis of a national project to reduce hypertension in Israel
title_full Cost-utility analysis of a national project to reduce hypertension in Israel
title_fullStr Cost-utility analysis of a national project to reduce hypertension in Israel
title_full_unstemmed Cost-utility analysis of a national project to reduce hypertension in Israel
title_sort cost-utility analysis of a national project to reduce hypertension in israel
publisher BMC
series Cost Effectiveness and Resource Allocation
issn 1478-7547
publishDate 2007-11-01
description <p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p>
url http://www.resource-allocation.com/content/5/1/16
work_keys_str_mv AT dickerdror costutilityanalysisofanationalprojecttoreducehypertensioninisrael
AT viskoperreuven costutilityanalysisofanationalprojecttoreducehypertensioninisrael
AT ginsberggary costutilityanalysisofanationalprojecttoreducehypertensioninisrael
AT yosefychaim costutilityanalysisofanationalprojecttoreducehypertensioninisrael
AT gavishdov costutilityanalysisofanationalprojecttoreducehypertensioninisrael
_version_ 1724835406283800576